The state of Texas currently has 16 active clinical trials seeking participants for NASH - Nonalcoholic Steatohepatitis research studies. These trials are conducted in various cities, including Houston, Dallas, San Antonio and Austin.
A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )
Recruiting
This Phase 3 study is conducted to evaluate lanifibranor in adults with NASH and liver fibrosis histological stage F2 or F3
Gender:
All
Ages:
18 years and above
Trial Updated:
01/24/2024
Locations: Texas Clinical Research Institute, Arlington, Texas +42 locations
Conditions: NASH - Nonalcoholic Steatohepatitis
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Patients With Presumed Nonalcoholic Steatohepatitis (NASH)
Recruiting
This phase 1b, Open-Label Study is to assess the safety, efficacy of miricorilant in patients with presumed Nonalcoholic Steatohepatitis (NASH)
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
09/28/2023
Locations: Site 211, Austin, Texas +3 locations
Conditions: Nonalcoholic Steatohepatitis (NASH)
Non-Invasive Quantification of Liver Health in NASH (N-QUAN)
Recruiting
To evaluate, in patients with suspected NASH referred for liver biopsy, the diagnostic performance of CT1 at discriminating those with NAS≥4 & F≥2 from those without.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
09/07/2023
Locations: Liver Center of Texas, Dallas, Texas
Conditions: NASH - Nonalcoholic Steatohepatitis
Safety, Tolerability, and Efficacy of AXA1125 in NASH With Fibrosis
Recruiting
This study will compare the effects of AXA1125, an orally active mixture of amino acids, compared to placebo, on improving fat and inflammation (steatohepatitis) as well as fibrosis in subjects with non alcoholic steatohepatitis (NASH). as well as the safety and tolerability of AXA1125. Subjects will take one of two different doses of AXA1125 or a placebo twice daily, and a liver biopsy will be done at the beginning and end of the 48-week study.
Gender:
All
Ages:
18 years and above
Trial Updated:
09/07/2022
Locations: Texas Clinical Research Institute, Arlington, Texas +11 locations
Conditions: Non Alcoholic Steatohepatitis (NASH)